Bio-Techne Corp. (TECH), a life sciences company, announced Tuesday that it has won a second claim of reverse engineering by Miltenyi ...
Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by ...
Bio-Techne Corp. TECH has launched a highly sensitive ESR1 mutation monitoring assay through its Asuragen brand. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+ ...
The stock's fall snapped a two-day winning streak.
Zacks.com on MSN2mon
Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up in PremarketBio-Techne TECH reported first-quarter fiscal 2025 adjusted earnings per share (EPS) of 42 cents, which exceeded the Zacks ...
MINNEAPOLIS, Nov. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical ...
In trading on Monday, shares of Bio-Techne Corp (Symbol: TECH) crossed above their 200 day moving average of $73.66, changing hands as high as $74.93 per share. Bio-Techne Corp shares are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback